Safety and Effectiveness Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the treatment of patients with COVID-19
This is a prospective, open-label, randomized, controlled clinical investigation designed to
evaluate the safety and effectiveness of the Exthera Medical Seraph 100 Microbind Affinity
Blood Filter in the treatment of patients with confirmed SARS-CoV-2 infection.
The clinical investigation will be conducted at 3 centers in Germany and at 2 centers in
Spain. Subjects will be randomized to the treatment group (Seraph 100 + standard of care)
versus control group (standard of care only).
Subjects will be followed for 28 days. For viral quantification, study-related serum samples
are done immediately before the initial treatment with Seraph 100 starts in the treatment
group or immediately after randomization into the control group. Additionally, serum sampling
at timepoint 12 hours is applicable for both treatment and control group.
Device: Seraph 100
Bloodfiltration with Seraph 100
Inclusion Criteria:
1. Subjects with confirmed SARS-CoV-2 infection
2. Be ≥ 18 years old and ≤90 years old
3. Acute respiratory distress syndrome assessed by a modified Sequential Organ Failure
Assessment score of at least 2 points
4. At least one additional organ dysfunction assessed by a modified Sequential Organ
Failure Assessment score of at least 1 point
5. Written or electronic consent of the subjects who are legally competent and have the
capacity to give consent
Exclusion Criteria:
1. Subject is currently participating in another clinical investigation
2. Pregnant or nursing subjects and those who plan pregnancy during the clinical
investigation follow-up period
3. Presence of comorbid conditions, or other medical, social, or psychological conditions
that, in the investigator's opinion, could limit the subject's ability to participate
in the clinical investigation or to comply with follow-up requirements, or impact the
scientific soundness of the clinical investigation results
4. Have Child-Pugh Class C cirrhosis
5. Have platelet count <30.000/uL
6. Contraindications for heparin sodium for injection
7. Subjects demonstrating any contraindication for this treatment as described in the IFU
8. Subjects with known allergy of polyethylene and copolyester
9. Subjects with hospital-acquired SARS-CoV-2 infections
10. Subject is held in an institution by court or official order
11. Subject is dependent on the sponsor or investigator so that consent can no longer be
considered voluntary
Klinikum Aschaffenburg-Alzenau
Aschaffenburg, Germany
Vivantes Klinikum Neukölln
Berlin, Germany
Universitätsklinikum Essen
Essen, Germany
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Clinico San Carlos
Madrid, Spain
Carla Kikken-Jussen
+ 31 43 8200 399
carla@extheramedical.com
Herwig Gerlach, Prof., Principal Investigator
Vivantes Neukoelln Berlin